Results 41 to 50 of about 8,788 (204)

The anti-COVID-19 drug nirmatrelvir crosses the blood‒brain barrier and exhibits herb–drug pharmacokinetic interactions with Scutellaria baicalensis formulations

Heliyon
Aim of the study: Our hypothesis is that nirmatrelvir can penetrate the blood‒brain barrier and reach effective concentrations in the brain. Furthermore, herbal formulations can help maintain nirmatrelvir levels in the body, suggesting potential ...
Wan-Hsin Lee, Yen-Ying Kung, Chung-Kai Sun, Chun-Hao Chang, Wen-Ya Peng, Lie-Chwen Lin, Chung-Hua Hsu, Muh-Hwa Yang, Tung-Hu Tsai   +8 more
doaj   +1 more source

From prediction to intervention: Paradigm shifts in causal AI for precision medicine and large‐scale cohorts

VIEW, EarlyView.
Large‐scale cohorts and multimodal biomedical data have enabled powerful predictive models for clinical risk stratification, but prediction alone cannot guide effective interventions. This review introduces causal artificial intelligence as a design‐first framework that integrates target trial emulation, causal discovery, and robust effect estimation ...
Linlin Cao, Yudian Xu, Yifan Chen, Honghao Huang, Wei Xu, Jun Pu   +5 more
wiley   +1 more source

Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model: A Cross-Sectional Study on Self-Management, Information, and Medication Impact

Journal of Patient Experience
In response to the COVID-19 pandemic, nirmatrelvir/ritonavir was approved as the first per os treatment to prevent severe disease progression. This study explores patients’ self-management of nirmatrelvir/r and its impact on their long-term medications ...
Beatriz Santos MS, Maeva Rousseau MS, Ralitza Gauthier PhD, Alexandra Calmy MD, PhD, Marie P. Schneider PhD   +4 more
doaj   +1 more source

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease [PDF]

Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear.
Antinori, Spinello, Bergna, Annalisa, Bernasconi, Davide, Borghetti, Silvia, Casalini, Giacomo, Colaneri, Marta, Colombo, Valeria, Corbellino, Mario, Cordier, Laura, Dedivitiis, Gianfranco, Fassio, Federico, Gabrieli, Arianna, Galli, Lucia, Gori, Andrea, Lai, Alessia, Riva, Agostino, Rizzardini, Giuliano, Scaglione, Giovanni, Schiavini, Monica, Sollima, Salvatore, Tarkowski, Maciej, Ventura, Carla Della, Visigalli, Debora   +22 more
core   +1 more source

Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study

Annals of Medicine
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19).
Xiaobo Han, Chenglong Li, Xin Yuan, Junchang Cui, Zhihai Han, Jiguang Meng, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Wei Chen, Junchen Xiong, Dahui Zhao, Xinxin Zhang, Xinjie Han, Haibo Cheng, Zhongkuo Yu, Yinghan Shi, Wuxiang Xie, Lixin Xie   +24 more
doaj   +1 more source

Bioequivalence study of generic nirmatrelvir in healthy volunteers

Фармация и фармакология (Пятигорск), 2023
Nirmatrelvir is an antiviral drug that, in combination with ritonavir, is an effective agent for the etiotropic therapy of patients with mild to moderate COVID-19.The aim of the study was to evaluate bioequivalence of the generic drug nirmatrelvir ...
R. A. Oseshnyuk, A. G. Nikiforova, A. Yu. Boroduleva, P. D. Sobolev, S. A. Lesnichuk, B. B. Garyaev, A. A. Abramova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, A. N. Dolgorukova, E. K. Khanonina, V. G. Ignatiev, M. Yu. Samsonov   +13 more
doaj   +1 more source

The Remarkable Selectivity of Nirmatrelvir

ACS Pharmacology & Translational Science, 2022
The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 Mpro but also minimal polypharmacology versus human cysteine proteases.
Damien Y. Duveau, Craig J. Thomas
openaire   +2 more sources

Paxlovid in Kidney Failure: A Review [PDF]

The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes.
Ardianty, Nonie, Hasmono, Didik, Suharjono   +2 more
core   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source